Pharmacopoeia Compliance Series
In this series of articles, J. Mark Wiggins, owner and compendial consultant with Global Pharmacopoeia Solutions LLC, and Joseph A. Albanese, director of Analytical Strategy and Compliance at Janssen Research and Development, LLC, provide an understanding about the need for pharmacopoeia compliance.
In this series of articles, J. Mark Wiggins, owner and compendial consultant with Global Pharmacopoeia Solutions LLC, and Joseph A. Albanese, director of Analytical Strategy and Compliance at Janssen Research and Development, LLC, provide an understanding about the need for pharmacopoeia compliance.
The following articles can be found within this series:
Why Pharmacopoeia Compliance is Necessary
Why Pharmacopoeia Compliance is Difficult
A Brief History of Pharmacopoeias: A Global Perspective
View PDFGlobal Pharmacopoeia Standards: Why Harmonization is Needed
Harmonization Efforts by Pharmacopoeias and Regulatory Agencies
View PDF
USP Permits Use of Non-Animal-Derived Reagents for Endotoxin Testing
July 29th 2024The US Pharmacopeia’s Microbiology Expert Committee approved the inclusion of a chapter into the United States Pharmacopeia–National Formulary that allows the use of non-animal-derived reagents for endotoxin testing.
